Perhaps China could use some genetically modified food.  Otherwise, meeting the food demands of 22 percent of the world's population while maintaining their over-reliance on nitrogen-based fertilizer will continue to dramatically increase their emissions of nitrous oxide (N₂O) – the most potent greenhouse gas. 

Medivir AB has announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Janssen will conduct a drug-drug interaction study with simeprevir and VX-135 to support the planned initiation of a phase II proof-of-concept study in early 2013, pending discussions with regulatory authorities. 

Keryx Biopharmaceuticals, Inc. has announced the initiation of a Phase 2 study of Zerenex (ferric citrate), an ferric iron-based phosphate binder drug candidate, in managing serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease ("NDD-CKD").

In the United States alone, over one and a half million people suffering from Stages 3 to 5 NDD-CKD have iron deficiency anemia, however, there are currently no oral iron supplements with an FDA label in NDD-CKD. Also, there are currently no FDA approved phosphate binders in NDD-CKD.

Glybera is the first gene therapy approved by regulatory authorities in the Western world. niQure announced it has received approval from the European Commission for the gene therapy Glybera(R) (alipogene tiparvovec), a treatment for patients with lipoprotein lipase deficiency (LPLD, also called familial hyperchylomicronemia) suffering from recurring acute pancreatitis.

Patients with LPLD, a very rare, inherited disease, are unable to metabolize the fat particles carried in their blood, which leads to inflammation of the pancreas (pancreatitis), an extremely serious, painful, and potentially lethal condition. The approval makes Glybera the first gene therapy approved by regulatory authorities in the Western world. 

While the goal of en enlightened society has always been food so plentiful and cheap that even poor people could afford to be fat, it hasn't been without pitfalls in the form of a looming crisis for society, caused by millions of people who are seriously overweight - that will be the topic of a University of Greenwich public lecture on November 28th.

Small critters tend to evolve into bigger beasts, according to paleontologist Edward Cope, what is now known as Cope's Rule.

Using statistical modeling methods, a new test of this rule as it applies dinosaurs says that Cope was right -- sometimes.  Which is statistically possible.